Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MDGL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Market Cap
Shares Outstanding
Share in Float
Dividende
Earning Date
No Data
Price Target
Average Volume
Beta
Range
Industry
Website
Sector
Earnings Growth
YoY
Current
Estimates
Sales Growth
YoY
Current
Estimates
Return on Equity
QoQ
Institutionnal Ownership
QoQ
Q3.23
N/A
-5.34
vs -4.75
Q4.23
N/A
-5.68
vs -4.98
Q1.24
N/A
-7.38
vs -4.23
Q2.24
N/A
-7.10
vs -4.69
Q3.24
N/A
-4.92
vs -5.34
Q4.24
N/A
-2.71
vs -5.68
Q1.25
N/A
-3.32
vs -7.38
Q2.25
N/A
-1.90
vs -7.10
Q3.25
N/A
-1.93
vs -4.92
Q4.25
N/A
-2.16
vs -2.71
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
14.6M vs NA
Q3.24
NA
62.2M vs NA
Q4.24
NA
103.3M vs NA
Q1.25
NA
137.3M vs NA
Q2.25
+1354%
212.8M vs 14.6M
Q3.25
+293%
244.2M vs 62.2M
Q4.25
+169%
278.1M vs 103.3M
Q1.23
-52%
-0.52
vs -0.44
Q2.23
-83%
-0.83
vs -0.52
Q3.23
-444%
-4.44
vs -0.83
Q4.23
-28%
-0.28
vs -4.44
Q1.24
-17%
-0.17
vs -0.28
Q2.24
-18%
-0.18
vs -0.17
Q3.24
-14%
-0.14
vs -0.18
Q4.24
-8%
-0.08
vs -0.14
Q1.25
-10%
-0.10
vs -0.08
Q2.25
-6%
-0.06
vs -0.10
Q1.23
248
248
vs 218
14%
Q2.23
238
238
vs 248
-4%
Q3.23
232
232
vs 238
-3%
Q4.23
257
257
vs 232
11%
Q1.24
312
312
vs 257
21%
Q2.24
288
288
vs 312
-8%
Q3.24
285
285
vs 288
-1%
Q4.24
321
321
vs 285
13%
Q1.25
341
341
vs 321
6%
Q2.25
319
319
vs 341
-6%
globenewswire.com
8 hours ago
247wallst.com
8 hours ago
zacks.com
13 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Relative Strength
MDGL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
555%2026-Revenue
302%2026-EPS
2265%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
initialisePrevious: Not converted
2024-06-28
Now: Neutral
Wolfe Research
initialisePrevious: Not converted
2024-06-10
Now: Outperform
Bank of America Securities
initialisePrevious: Not converted
2024-04-22
Now: Underperform
Raymond James
upgradePrevious: Not converted
2022-12-19
Now: Market Perform
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-9.62Â ( -2.25%)
Relative Strenght
88
Volume Buzz
-30%
Earning Acce
No
Dist 52w H.
9%